Pancreatic Circulating Tumor Cells: An Update
Onco · 13.02.2026 · 6 (1) · 13
DOI: 10.3390/onco6010013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Onco, online erschienen am 13.02.2026. Verfasst von Nerea Laura Keller und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by late diagnosis, early metastasis, and poor response to therapy. Liquid biopsy approaches, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes, offer a minimally invasive method to monitor tumor burden, progression, and treatment response in real time. This review aims to synthesize recent findings on CTCs in PDAC, evaluate detection technologies, and explore their clinical and translational potential.
Methods
We conducted a comprehensive literature search using PubMed and Google Scholar, focusing on original studies and reviews published within the past 15 years. Articles were selected based on relevance to CTC biology, detection methods, clinical correlations, and integration with other biomarkers. Attention was paid to studies published since 2018 and landmark earlier works.
Results
CTCs are detectable in PDAC patients and are consistently associated with worse survival and higher recurrence rates. However, detection sensitivity varies widely by method. EpCAM-based platforms like CellSearch® detect CTCs in ~7–48% of cases, while newer size-based and microfluidic approaches report rates above 75%. CTCs exhibit epithelial–mesenchymal and stem-like phenotypes and can form clusters with high metastatic potential. Recent studies demonstrate molecular heterogeneity and show that CTC-derived organoids are feasible for functional studies. Nonetheless, technical variability and the lack of standardization remain major obstacles.
Conclusions
CTCs represent a promising biomarker for prognosis and treatment monitoring in PDAC. Further refinement of enrichment techniques, molecular profiling strategies, and prospective clinical validation are needed to integrate CTC assays into routine PDAC management.
Zitieren
APA
Keller, N. L., Votta-Velis, G., Aguirre, J. A., & Borgeat, A. (2026). Pancreatic Circulating Tumor Cells: An Update. Onco, 6(1), 13. https://doi.org/10.3390/onco6010013
Vancouver
Keller NL, Votta-Velis G, Aguirre JA, Borgeat A. Pancreatic Circulating Tumor Cells: An Update. Onco. 2026;6(1):13. doi:10.3390/onco6010013
BibTeX
@article{Keller2026,
author = {Keller, Nerea Laura and Votta-Velis, Gina and Aguirre, José Alejandro and Borgeat, Alain},
title = {Pancreatic Circulating Tumor Cells: An Update},
journal = {Onco},
year = {2026},
volume = {6},
number = {1},
pages = {13},
doi = {10.3390/onco6010013}
}
EUVIMED